Arcus Biosciences, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| RCUS | IDYA | 688382.SS | 2256.HK | SNDX | AAPG | |
|---|---|---|---|---|---|---|
| Market cap | 2.43B | 3.12B | 8.38B | 5.03B | 940.80M | 1.41B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -6.2 | -7.9 | -43.8 | -24.1 | -14.4 | -23.3 |
| Price/book | 3.8 | 2.9 | 6.6 | 2.0 | -54.7 | 16.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −4.25% | +5.63% | −48.70% | −54.94% | −5.36% | −59.04% |
| Today | +2.12% | +3.29% | +4.33% | +6.85% | −26.87% | +11.75% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All RCUS news ›Arcus Biosciences Announces New Employment Inducement Grants - October 9, 2026
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.…
More from 1 other outlet
Arcus Biosciences: late-line median survival 35 months
Celestica Announces Third Quarter 2026 Financial Results and Will Hold 2026 Investor and Analyst Day HeartBeam’s Heart Attack Assessment Technology Accepted into FDA’s Total Product Life Cycle Advisory Program (TAP) Quantum Cyber Invited…
Arcus Biosciences reports $694M cash for pipeline advancement through pivotal trials
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends. Arcus Biosciences reports $694M cash for pipeline advancement…
Arcus Biosciences slides 20% on stock offering, kidney-cancer data
Arcus Biosciences (RCUS) stock sank 20% after casdatifan kidney-cancer data and a public offering. SA Spotlight uses AI to summarize content published on Seeking Alpha. All summaries are reviewed by human editors prior to publication.…
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Jefferies, Leerink Partners, TD Cowen, Evercore ISI and Mizuho are acting as joint book-running managers for the offering. About Arcus Biosciences, Inc. Arcus Biosciences is a late clinical-stage biopharmaceutical company focused on…
More from 1 other outlet
Arcus Biosciences prices $250M public offering at $17.50 per share
Arcus Biosciences stock fell after pricing a $250M public offering at $17.50 per share. - Arcus Biosciences (RCUS) stock price slipped about 6% on Thursday pre-market hours as the company priced its public offering of 14,285,715 common…
Arcus Biosciences (NYSE:RCUS) Stock Gets Price Target Boost from Truist Financial
Posted by Danessa Lincoln on Oct 21st, 2026 Arcus Biosciences (NYSE:RCUS – Get Free Report) had its target price boosted by investment analysts at Truist Financial from $40.00 to $41.00 in a research report issued on Wednesday, Benzinga…
Arcus Biosciences (NYSE:RCUS) Stock Price Expected to Rise, Wedbush Analyst Says
Posted by Danessa Lincoln on Oct 21st, 2026 Arcus Biosciences (NYSE:RCUS – Get Free Report) had its price objective raised by research analysts at Wedbush from $43.00 to $49.00 in a note issued to investors on Wednesday, Benzinga reports.…
Analysts Are Bullish on Top Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), Arcus Biosciences (RCUS)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rhythm Pharmaceuticals (RYTM), Arcus Biosciences (RCUS) and Cytokinetics (CYTK) with bullish sentiments. In a report released today, Seamus…
Mizuho Optimistic on Arcus Biosciences (RCUS) After Casdatifan Data Boost
This profile highlights that while Arcus’s recent momentum and clinical progress are encouraging, the company remains financially fragile with weak profitability and growth fundamentals. Investors should weigh these factors carefully…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net5
- seekingalpha.com4
- themarketsdaily.com4
- gurufocus.com2
- biospace.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 20 articles, not a forecast.